The $2.2 billion acquisition of Spectranetics was completed by Royal Philips, making Spectranetics a part of its Image-Guided Therapy Business Group. Spectranetics makes a drug-coated angioplasty balloon, a medical laser and catheters for treating patients with blockages in leg and coronary arteries, as well as to remove infected pacemaker leads.
Royal Philips closes $2.2B deal to buy Spectranetics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.